Wednesday, February 10, 2010, 2:29PM AEST - The Australian Stockmarket closes in 1 hour and 36 minutes.
To create a watchlist or portfolio of shares, Register

Insmed Incorporated (INSM)

8:00AM AEST: 0.81 USD  Up 0.01 (0.62%)  
 MORE ON INSM 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Insmed, Inc. (NCM:INSM) Delayed quote dataEdit
Last Trade:0.81 USD
Trade Time: 8:00AM AEST
Change:Up 0.01 (0.62%)
Prev Close:0.81
Open:0.82
Bid:0.75 x 400
Ask:0.83 x 2600
1y Target Est:2.00
Day's Range:0.80 - 0.83
52wk Range:0.41 - 2.57
Volume:459,079
Avg Vol (3m):615,205
Market Cap:105.47M
P/E (ttm):0.91
EPS (ttm):0.90
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add INSM to Portfolio   Download Data

 HEADLINES 
Under the Radar Developments at Insmed
at Seeking Alpha (Sun, Jan 31)
The Schloss Screen for 2010
RealMoney by TheStreet.com (Thu, Jan 7)
Old School Value Stock Portfolio Performance 2009
at Seeking Alpha (Wed, Jan 6)
Buy a Company, Get the Plant for Free
at Motley Fool (Sat, Dec 19)
8 Cheap Stocks Trading Below Net Net Working Capital
at Seeking Alpha (Mon, Dec 14)
4 More Stocks on Wall Street's Dollar Menu
at Motley Fool (Tue, Dec 8)
INSMED INC Financials
EDGAR Online Financials (Sat, Nov 14)
INSMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Sat, Nov 7)
Insmed Incorporated Earnings Call scheduled for 8:30 am ET today
CCBN (Sat, Nov 7)
Sirius Breaks the Buck
at Motley Fool (Sat, Sep 19)
INSMED INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transf
EDGAR Online (Thu, Sep 17)
INSMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Thu, Aug 13)
5 More Stocks on Wall Street's Dollar Menu
at Motley Fool (Thu, Aug 13)
More Headlines for INSM...

 ANALYST 
EPS Est (next year) (Dec-09) :N/A
EPS Est (in 2 years) (Dec-10) :N/A
Avg Rec (current)*:1.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Insmed Incorporated, a development stage company, engages in the development of recombinant protein drug. The company’s primary product includes IPLEX, a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatm...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices